Tag Archives: CiPA

2021 CiPA in-silico Modelling Workshop

Posted on June 14, 2021 by Gary Mirams

Abstract submission for the 2021 CiPA in-silico modelling meeting is open now. Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Ion Channel Models, Model Development, Safety Pharmacology | Tagged , , , , , , | Leave a comment

A report on the Toronto CiPA in-silico modelling workshop

Posted on July 16, 2018 by Gary Mirams

This is a follow-up to this post advertising the workshop. On the 9th November 2017 the CiPA in-silico Working Group hosted a meeting in Toronto General Hospital that the Cardiac Physiome meeting kindly let us run as a satellite meeting … Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Ion Channel Models, Model Development, Safety Pharmacology | Tagged , , , , , , , | 2 Comments

Postdoc position available

Posted on September 4, 2017 by Gary Mirams

N.B. This position is now closed. Another short post, just to advertise a postdoctoral research associate (PDRA) position available to work with me. It’s a two year position, based at the Centre for Mathematical Medicine & Biology at the University … Continue reading →

Posted in Drug action, Experimental Design, Future developments, Ion Channel Models, Model Development, Safety Pharmacology, Stats and Inference | Tagged , , | Leave a comment

CiPA in-silico modelling meeting

Posted on August 31, 2017 by Gary Mirams

There’s an effort underway to evaluate, improve and implement mathematical models of cardiac electrophysiology for pharmaceutical cardiac safety testing and regulatory practice. In particular, to be part of a more mechanistic and accurate in-vitro assessment of pro-arrhythmic risk than the … Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Ion Channel Models, Model Development, Safety Pharmacology | Tagged , , | 1 Comment

Arrhythmic risk: regression, single cell biophysics, or big tissue simulations?

Posted on March 27, 2017 by Gary Mirams

On the 15th March I presented at an FDA public Advisory Committee hearing on the proposals of the CiPA initative. CiPA aims to replace the current testing for increased drug-induced Torsade de Pointes (TdP) arrhythmic risk, which is a human … Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Model Development, Safety Pharmacology, Tissue Simulations | Tagged , , , , , , , | 3 Comments